SELLAS Life Sciences Group, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. SELLAS is a clinical-stage biopharmaceutical company developing GPS, a WT1-targeted cancer immunotherapy, and GFH009, a CDK9 inhibitor. It generated no product-sales revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 or prior balance |
|---|---|---|
| Licensing revenue | $0 | $1.0 million |
| Research and development expense | $7.2 million | $4.6 million |
| General and administrative expense | $4.1 million | $3.0 million |
| Total operating expenses | $11.3 million | $17.7 million |
| Operating loss | $11.3 million | $16.7 million |
| Net loss | $11.1 million | $16.7 million |
| Basic and diluted loss per share | $(0.47) | $(1.05) |
| Cash and cash equivalents at period end | $23.9 million | $17.1 million at December 31, 2022 |
| Restricted cash | $0.1 million | $0.1 million at December 31, 2022 |
| Cash used in operating activities | $12.1 million | $7.2 million |
| Current liabilities | $15.5 million | $15.5 million at December 31, 2022 |
Net financing cash inflow was $18.9 million, principally from the February public offering; total cash, cash equivalents, and restricted cash increased by $6.8 million. The filing reports no conventional borrowings. Current liabilities include a $5.5 million acquired in-process research and development payable due June 1, 2023. Profit margins are not meaningful given the absence of product sales.
Material changes versus Q1 2022
- Net loss narrowed by $5.6 million, largely because Q1 2022 included a $10.0 million acquired in-process R&D charge for the GFH009 license. Excluding that item, operating expenses rose: R&D increased $2.6 million and G&A increased $1.1 million.
- Q1 2022 licensing revenue of $1.0 million reflected a 3DMed milestone; no licensing revenue was recognized in Q1 2023.
- Operating cash use increased by $5.0 million year over year. The company raised approximately $18.5 million net in its February 2023 offering and approximately $0.3 million net under its equity sales agreement.
- Shares outstanding rose from 21.0 million at year-end to 28.3 million at March 31. The February offering issued 7.22 million shares with warrants to purchase an additional 7.22 million shares at $2.77 each, exercisable through February 2028.
Outlook, risks, and unusual items
- Going concern: Management stated that available cash would not fund planned operations for at least the next 12 months from issuance of the financial statements, and disclosed substantial doubt about the company’s ability to continue as a going concern. Additional financing is required; absent funding, it may scale back plans or put activities on hold. The filing identifies no committed funding source other than its equity sales agreement, with approximately $39.2 million of capacity remaining at March 31.
- Potential 3DMed milestone: Participation by 3DMed in the REGAL study was expected to trigger $13.0 million in payments before the end of Q3 2023. The payments were variable, outside SELLAS’s control, and excluded from its going-concern assessment. A further $191.5 million of potential development, regulatory, and sales milestones remains under the license, excluding royalties; these are not assured.
- Clinical outlook: Management expected the event-driven interim analysis of the GPS Phase 3 REGAL study around year-end 2023 or early 2024 and final analysis by year-end 2024, subject to enrollment and event timing. It expected topline data from the GPS/nivolumab mesothelioma study in Q2 2023 and final GPS/pembrolizumab ovarian-cancer data in Q4 2023. GFH009 lymphoma-group analyzed data were expected in Q3 2023; a Phase 2a GFH009 combination study in AML was planned for Q2 2023, with topline data expected in Q4 2023.
- The filing also reports, after quarter-end, completion of the highest-dose safety evaluation in the GFH009 AML Phase 1 group and May 2023 positive topline AML data, with an AML recommended Phase 2 dose established and submitted to FDA. These are company-reported updates, not Q1 financial results.
- Clinical development, regulatory approval, patient enrollment, financing availability, and future partnership or licensing revenue remain significant uncertainties. The expected REGAL analyses are event-driven and may occur later or earlier than projected. No pending or threatened litigation was reported at March 31, 2023.
Investor facts to verify
- Whether SELLAS secured sufficient financing after the filing to address the disclosed 12-month funding shortfall, including the timing and terms of any equity issuance.
- Whether the expected $13.0 million 3DMed payments were triggered and received, and whether the REGAL China participation and clinical timelines progressed as anticipated.
- Current trial enrollment, event counts, results, and regulatory status for GPS and GFH009; distinguish company topline updates from peer-reviewed or regulator-reviewed evidence.
- Potential dilution from the 12.36 million warrants outstanding at March 31, 2023, plus other reserved shares, and the effects of future use of the equity sales agreement.
- Whether operating cash burn, the $5.5 million GenFleet payment, and other clinical obligations changed the company’s liquidity outlook.